Defining how the molecular constituents of the tight junction interact is a prerequisite to understanding tight junction physiology. We utilized in vitro binding assays with purified recombinant proteins and immunoprecipitation analyses to define interactions between ZO-1, ZO-2, ZO-3, occludin, and the actin cytoskeleton. Actin cosedimentation studies showed that ZO-2, ZO-3, and occludin all interact directly with F-actin in vitro, indicating that actin is engaged in multiple interactions at the tight junction. Low speed sedimentation analyses demonstrated that neither ZO-2, ZO-3, nor occludin act as F-actin cross-linking proteins, and further evidence indicates that these proteins do not bind to actin filament ends. The binding interactions of ZO-2, ZO-3, and occludin were corroborated in vivo by immunofluorescence colocalization experiments which showed that all three proteins colocalized with actin aggregates at cell borders in cytochalasin D-treated Madin-Darby canine kidney cells. Exploration of other tight junction protein interactions demonstrated that ZO-2 binds directly to both ZO-1 and occludin. Contrary to previous beliefs, our immunoprecipitation results indicate that ZO-1, ZO-2, and ZO-3 exist in situ primarily as independent ZO-1⅐ZO-2 and ZO-1⅐ZO-3 complexes rather than a trimeric ZO-1⅐ZO-2⅐ZO-3 grouping. These studies elucidate direct binding interactions among tight junction-associated proteins, giving insight into their organization as a multimolecular structure.
The molecular composition of the TJ is now beginning to be described. Since the identification and characterization of the first TJ protein ZO-1 (2), a host of other proteins which localize to the TJ have been identified. The peripheral membrane proteins ZO-2 (3, 4) and ZO-3 (5), together with ZO-1, are members of the MAGUK family of proteins (6) displaying a characteristic multidomain structure comprised of the PDZ, SH3, and guanylate kinase-like (GUK) domains. ZO-1, ZO-2, and ZO-3, unlike other members of the MAGUK family, each also have an acidic domain, a basic arginine-rich region, and a proline-rich domain. Other peripheral membrane proteins localized to the cytoplasmic surface of the TJ include cingulin (7), symplekin (8) , 7H6 (9), Rab3B (10), the Ras target AF-6 (11), and ASIP, an atypical protein kinase C interacting protein (12) . Some of these proteins are believed to act in signal transduction events, indicating that TJ barrier dynamics may be regulated locally by signaling events within the TJ plaque. Transmembrane protein components of the TJ include occludin (13) , JAM (14) , and the claudin family of proteins (15, 16) , which includes paracellin-1 (17) .
Actin filaments are known to be associated with the TJ cytoplasmic plaque (18, 19) and are believed to act in the regulation of TJ permeability (20, 21) . The mechanism through which actin acts has not been determined directly, although several investigators propose a linkage of actin⅐ZO-1⅐occludin based on cosedimentation studies using the C-terminal half of ZO-1 (22, 23) . However, it is possible that the observed ZO1⅐actin interaction is due to unidentified intermediary proteins as actin binding was assayed from whole cell lysates. Evidence exists that occludin, and not other transmembrane elements of the TJ, functions in the linkage between the TJ and the actin cytoskeleton (24) . Itoh et al. (25) have hypothesized that ZO-2 also interacts with the actin cytoskeleton, as an exogenously expressed C-terminal ZO-2 construct distributes along actin stress fibers in fibroblasts.
Limited information exists regarding interactions among TJassociated proteins. ZO-1, ZO-2, and ZO-3 can be coimmunoprecipitated from MDCK cells (3, 5, 26) . It is known that ZO-1 can directly bind to the cytoplasmic C-terminal tail of occludin (22, 27) and the Ras-effector molecule AF-6 (11) . We have previously shown via in vitro binding assays that ZO-3 interacts directly with ZO-1 and the cytoplasmic C-terminal tail of occludin, but does not bind ZO-2 (5). Based on immunoprecipitation of protein constructs from transfected cells, recent reports suggest that ZO-1 and ZO-2 interact with each other via their second PDZ domains (22, 25) . However, these binding studies were also performed with whole cell lysates, and the possibility that the interaction is indirect and mediated by other proteins cannot be excluded. Recent data suggest that the N terminus of ZO-2 also interacts with the C-terminal tail of occludin (25) , although again, this was assayed using whole cell lysates.
Defining how the molecular components of the TJ interact will provide information crucial to understanding TJ physiology. Here we define the interactions between ZO-1, ZO-2, ZO-3, occludin, and F-actin through the use of purified proteins in in vitro binding assays. Our data show that the interactions between the actin cytoskeleton and junctional components are more complex than anticipated, consisting of multiple possible linkage mechanisms. In addition, our results reveal that previous views on the existence of a three-member complex of ZO-1, ZO-2, and ZO-3 require revision. The emerging complexity of protein-protein interactions at the TJ has both functional and regulatory implications.
EXPERIMENTAL PROCEDURES

Protein Expression
Recombinant protein expression and purification was performed according to previously published methods (5) . In brief, full-length 6-histidine tagged ZO-3 (pHTc/ZO-3) and ZO-2 (pHTb/ZO-2) proteins were each expressed in Sf9 insect cells using a Baculovirus eukaryotic expression system (Life Technologies, Inc., Gaithersburg, MD). Empty pFastBac vector (pHTc), coding for the 6-histidine tag plus 36 nonspecific amino acids served as negative control. Protein from Sf9 cell lysate was purified on Probond nickel resin (Invitrogen Corp.), eluted with 300 -500 mM imidazole, and used in binding assays or cosedimentation experiments. JShak2, a 6-histidine tagged jellyfish Shaker-type K ϩ -channel peptide (amino acids 402-476; Ref. 28 , a gift from Dr. Warren Gallin, University of Alberta) in the pRSET expression vector (Invitrogen Corp., San Diego, CA) served as a negative control for ZO-2 and ZO-3/actin cosedimentation studies. GST-occludin cDNA encoding the cytoplasmic C-terminal tail (amino acids 358 -505) of chicken occludin (13) in pGEX-2T (a gift from Drs. Jim Anderson and Alan Fanning, Yale University), and GST alone were expressed according to the manufacturer's protocol (Amersham Pharmacia Biotech). GST fusion proteins were purified on glutathione-Sepharose 4B resin (Amersham Pharmacia Biotech) and eluted with 50 mM reduced glutathione. [ 35 S]Methionine-labeled in vitro transcribed/translated ZO-1 was prepared with the TNT TM T7-coupled reticulocyte system (Promega Corp.) using as template full-length human ZO-1 cDNA (obtained from Drs. Anderson and Fanning) in pBluescript SKϩ under control of the T7 promoter.
Antibodies
The following antibodies were used: rat anti-ZO-1 mAb R40.76 (29) , rabbit anti-ZO-2 polyclonal Ab R9989 (3), guinea pig anti-ZO-3 (5), and rabbit anti-vesicular stomatitis virus glycoprotein (a gift from Carolyn Machamer, Johns Hopkins University, Baltimore, MD). The anti-ZO-3 antibody does not cross-react with ZO-1 or ZO-2. A rabbit anti-occludin antibody (raised against amino acids 255-510) (Ref. 30 ; a gift from Drs. Alpha Yap and Barry Gumbiner) was used for immunoblot detection of both recombinant occludin and GST alone as it was raised against a GST fusion protein. A second rabbit anti-occludin antibody raised against the most C-terminal 150 amino acids (Zymed Laboratories Inc., San Francisco, CA) was used for immunofluorescence experiments. A mixture of anti-tetra-His and anti-penta-His antibodies (Qiagen, Valencia, CA) was used to recognize the 6-histidine tag of the JShak2 fusion protein. Horseradish peroxidase-conjugated goat anti-rabbit (Bio-Rad), horseradish peroxidase-conjugated goat anti-guinea pig (Jackson ImmunoResearch Laboratories, Inc.), and rhodamine-conjugated donkey anti-rabbit (Jackson ImmunoResearch Laboratories, Inc.) were used as secondary antibodies for immunoblots and indirect immunofluorescence. Immunoblot detection via ECL (Amersham Pharmacia Biotech) was performed according to manufacturer protocols.
Actin Cosedimentation Experiments and Low Speed Sedimentation Analysis
Actin cosedimentation experiments were performed according to modification of the methods of Fanning et al. (22) . Briefly, lyophilized G-actin (Ͼ95% pure grade) (Cytoskeleton Inc., Denver, CO) was diluted to 10 mg/ml with distilled water, so that buffer conditions were then 10 mM Tris-HCl, 0.2 mM ATP, 0.2 mM CaCl 2 , 1% dextran, 5% sucrose. Further dilution with actin binding buffer (10 mM imidazole, pH 7.2, 75 mM KCl, 5 mM MgCl 2 , 0.5 mM dithiothreitol) to a final actin concentration of 2.5 mg/ml was followed by 30 min incubation on ice to initiate polymerization. Polymerized F-actin was stabilized by adding phalloidin (Sigma) to 25 g/ml (22) . Purified ZO-2, ZO-3, JShak2, GST-occludin, or GST were dialyzed into actin binding buffer containing 0.1% Triton X-100 to inhibit aggregate formation, then pre-centrifuged at 100,000 ϫ g for 30 min. F-actin binding was assayed in 100-l reactions containing a final concentration of 0.25 mg/ml F-actin (or actin binding buffer alone), and precentrifuged purified test protein. Each reaction was incubated at room temperature for 30 min before spinning 30 min at 100,000 ϫ g. The supernatant fraction was removed and pellets were resuspended in an equal volume of gel sample buffer to maintain equivalent stoichiometry between supernatant and pellet fractions. Samples were run on SDS-PAGE and processed for immunoblotting. For actin cosedimentation assays using sheared actin, shearing was accomplished by pipetting the F-actin solution 20 times through a narrow bore pipette tip. Shearing of F-actin was confirmed by falling ball viscometry (31) to measure relative viscosity of unsheared versus sheared F-actin solutions. Test proteins were added to unsheared or sheared F-actin immediately after shearing.
Low speed sedimentation analysis was performed according to established methods (32) . Briefly, 100-l reactions containing 0.25 mg/ml actin alone, or in the presence of purified ZO-2, ZO-3, or occludin were incubated for 30 min at room temperature before centrifugation at 10,000 ϫ g in a benchtop microcentrifuge for 20 min. The supernatants were removed, and the pellet fractions were resuspended in an equal volume of gel sample buffer. Supernatant and pellet fractions were run on SDS-PAGE and stained with Coomassie Brilliant Blue to detect F-actin.
Cytochalasin D Experiments
Control MDCK (strain II) and MDCK cells expressing exogenous vesicular stomatitis virus glycoprotein-tagged ZO-3 (MDCK/Z3) (5) were grown on rat tail collagen-coated coverslips to near confluency. Cytochalasin D experiments were performed according to established methods (33) . Briefly, coverslips were treated for 60 min with either 2 g/ml cytochalasin D (from a 5 mg/ml dimethyl sulfoxide stock) or an equal concentration of dimethyl sulfoxide alone as a negative control. Cells were then immediately fixed with 2.5% paraformaldehyde and permeabilized with 0.2% Triton X-100 in TBS and fixed for immunofluorescence as described (34) . Fluorescein isothiocyanate-conjugated phalloidin (Sigma) was used to stain F-actin. Coverslips were viewed on a Zeiss Axioskop (Carl Zeiss, Inc., Oberkochen, Germany). For costaining experiments, control coverslips stained for ZO-2, ZO-3, occludin, or actin alone showed no visible fluorescence from either fluorochrome when viewed with the opposite filter set (data not shown).
Direct Binding: Affinity Chromatography
ZO-2/ZO-1 Binding-Negative control peptide from cells containing pHTc alone, or purified ZO-2 dialyzed against phosphate-buffered saline was bound to Probond resin and washed with phosphate wash buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 25 mM imidazole) with 0.2% Tween 20, 0.2% Triton X-100, and protease inhibitors (1 g/ml aprotinin, 0.2 mM phenylmethylsulfonyl fluoride, 1 g/ml chymostatin, 1 g/ml leupeptin, and 1 g/ml pepstatin). Protein-containing resin was incubated with the completed ZO-1 in vitro transcription/translation reaction diluted so that final binding conditions were 140 mM KCl, 25 mM imidazole, 10 mM HEPES, 0.1% Tween 20, 0.1% Triton X-100, and protease inhibitors. Binding proceeded overnight at 4°C, followed by washing with phosphate wash buffer with 0.1% Triton X-100 and 0.1% Tween 20. Washed resin was resuspended in gel sample buffer, boiled, and bound protein complexes were run on SDS-PAGE. Enhancement of 35 S signal was accomplished by sequential incubation of the gel in 40% methanol, 10% acetic acid (30 min), and 1 M salicylic acid solution (30 min). The gel was dried and exposed to Fuji RX film (Fuji Photo Film Co. Ltd., Japan).
ZO-2/Occludin Binding-GST-occludin or GST alone was purified on glutathione-Sepharose 4B beads, and Probond-purified ZO-2 was added. Final binding conditions were 140 mM KCl, 10 mM HEPES, pH 7.5, 1 mM MgCl 2 , 0.1% Triton X-100, and 0.1% Tween 20. Binding was allowed to proceed overnight at 4°C. After washing with the same buffer, bound protein was eluted by boiling the beads in gel sample buffer, resolved on SDS-PAGE, electrophoretically transferred, and immunoblotted with corresponding antibodies.
Immunoprecipitation Experiments
Low Stringency Immunoprecipitation-MDCK or MDCK/Z3 cells were grown and metabolically labeled as described previously (29, 35) . Low stringency immunoprecipitations, defined as conditions that maintain some protein-protein interactions, were performed according to previously published techniques (3, 5, 36) . Confluent monolayers of MDCK cells were solubilized as described, and centrifuged at 13,000 ϫ g for 10 min at 4°C to remove cell debris. In experiments requiring equivalent starting material, total protein concentration of the supernatant fraction was determined by BCA protein assay (Pierce, Rockford, IL) prior to immunoprecipitation. This supernatant was then immunoprecipitated with anti-ZO-1 mAb followed by goat anti-rat IgG coupled to cyanogen bromide-activated Sepharose 4B (Amersham Pharmacia Biotech), anti-ZO-2 followed by protein A-Sepharose, or anti-ZO-3 followed by protein A-Sepharose. Sepharose beads were washed according to the procedures of Pasdar and Nelson (37) and solubilized in gel sample buffer before running on SDS-PAGE and processing for autoradiography.
Sequential Immunoprecipitation-Low stringency immunoprecipitation followed by high stringency immunoprecipitation was performed with modification of previously published techniques (38) . Metabolically labeled MDCK cells were first immunoprecipitated under low stringency conditions (described above), and the resulting immune complexes were eluted from the Sepharose beads under high stringency conditions (39) by boiling in 1% SDS, 10 mM Tris-HCl, pH 7.5, 2 mM EDTA, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride to dissociate protein complexes. The supernatants were adjusted to 0.2% SDS by dilution with 50 mM Tris, pH 7.4, 190 mM NaCl, 10 mM EDTA, 2.9% Triton X-100, before reimmunoprecipitating a second time with the indicated antibodies.
RESULTS
Actin-Tight Junction Linkages-Although actin filaments have been observed at the TJ (18, 19) and have been implicated in the regulation of junction permeability (20, 21) , the linkage through which this interaction is mediated has not been unequivocally demonstrated. Previous work (22, 23) suggested an association between actin and ZO-1, although these experiments did not rule out the possibility that the interaction occurs via intermediary proteins.
We performed a series of actin cosedimentation assays to test directly the F-actin binding ability of other TJ proteins, using purified recombinant ZO-2 and ZO-3. We also tested the Factin binding ability of occludin to determine if linkage to the cytoskeleton is mediated exclusively by peripheral membrane proteins or if actin can bind directly to a transmembrane element. The actin cosedimentation assay is based on the observation that polymerized actin filaments are readily pelleted by high-speed centrifugation (Fig. 1A) . When ZO-2 (Fig. 1B) is added to the reaction, there is a significant shift of ZO-2 from the supernatant to the pellet fraction only in the presence of F-actin. A negative control protein ((His) 6 -tagged JShak2 fusion protein) did not cosediment with F-actin (Fig. 1B) , indicating that the ZO-2/actin association is not due to the 6-histiding tag binding F-actin. Furthermore, ZO-2 still cosedimented with F-actin after the 6-histidine tag had been removed by Factor Xa cleavage (data not shown). ZO-3 was similarly found to cosediment with F-actin (Fig. 1C) . Interestingly, GST-occludin was also found to cosediment specifically with F-actin, while the GST alone negative control peptide did not (Fig. 1D) . ZO-2, ZO-3, and occludin proteins also cosedimented with F-actin when spun through a 10% glycerol cushion (data not shown), further indicating that the observed interactions with actin are specific and are not due to trapping by actin filaments. Combined, these data suggest that F-actin is capable of specifically binding multiple TJ proteins.
F-actin binding proteins can be classified based on the type of interaction with actin. For example, there are F-actin endbinding (capping) proteins such as CapZ (40) , side binding proteins (non-cross-linking) such as tropomyosin (41), and cross-linking proteins such as ␣-actinin (42). We tested if ZO-2, ZO-3, and occludin bind to actin filament ends by utilizing actin cosedimentation experiments with unsheared versus sheared actin filaments. Shearing creates shorter actin filaments and therefore more actin ends available for binding. Confirmation of shearing was done by falling ball viscometry, which is a means of measuring relative viscosity of a solution. Our shear conditions resulted in a significant decrease in viscosity. We observed a fall rate of 0.69 cm/s Ϯ 0.035 for unsheared F-actin and 0.90 cm/s Ϯ 0.025 for sheared F-actin. The amount of pelletable F-actin did not change after shearing (Fig. 2A) . We conclude that these shear conditions result in a greater number of F-actin ends. When ZO-2, ZO-3, or occludin was incubated with either unsheared (Ϫ) or sheared (ϩ) actin filaments, there was no change in the amount of test protein found in the pellet ( Fig. 2A) , indicating that these proteins do not preferentially bind to F-actin ends.
F-actin side-binding proteins can act as cross-linkers if they have the ability to bind to more than one actin filament simultaneously. To test ZO-2, ZO-3, and occludin for actin filament cross-linking ability, we performed low speed sedimentation assays by centrifugation at 10,000 ϫ g for 20 min (32) . Under these conditions, the majority of single actin filaments remain in the supernatant (Fig. 2B) , whereas cross-linked filament networks readily pellet. Incubating ZO-2, ZO-3, or occludin with F-actin did not cause an increase in the amount of F-actin pelleted under these conditions (Fig. 2B) , suggesting that these proteins do not act to cross-link or bundle F-actin.
While the cosedimentation experiments indicate that ZO-2, ZO-3, and occludin bind F-actin directly in vitro, we further explored if these interactions were functionally relevant in vivo. Earlier work showed that treating cells with the actindisrupting drug cytochalasin D causes the continuous apical actin belt to reorganize into focal aggregates along cell boundaries, and that these aggregates colocalize with aggregates of ZO-1 (33) . A corresponding increase in paracellular permeability was also observed in the cytochalasin D-treated monolayers. To investigate if ZO-2, ZO-3, or occludin also associated with FIG. 1. Purified, recombinant ZO-2, ZO-3 , and occludin specifically cosediment with F-actin. A, Coomassie Blue-stained gel of phalloidin-stabilized F-actin alone centrifuged at 100,000 ϫ g. Equivalent aliquots of supernatant and pellet fractions were loaded. Polymerized F-actin is found almost entirely in the pellet. B, ZO-2 binds F-actin specifically. ZO-2 or a negative control 6-histidine tagged protein were incubated in the presence (ϩ) or absence (Ϫ) of F-actin, centrifuged at 100,000 ϫ g, and equivalent supernatant and pellet fractions were loaded and immunoblotted for ZO-2 or the 6-histidine tag. ZO-2 is associated with the pellet fraction only in the presence of F-actin. The 6-histidine-tagged protein JShak2 does not cosediment with actin. C, ZO-3 binds F-actin. ZO-3 was incubated in the presence (ϩ) or absence (Ϫ) of F-actin, treated as in part B, and immunoblotted for ZO-3. ZO-3 is associated with the pellet fraction only in the presence of F-actin. D, the C terminus of occludin binds F-actin. GST-occludin or GST alone were incubated in the presence (ϩ) or absence (Ϫ) of F-actin, treated as in B and C, and immunoblotted for GST-occludin. GST-occludin is associated with the pellet fraction only in the presence of F-actin. GST alone does not cosediment with actin.
actin filaments in vivo, cytochalasin D-treated or control monolayers were costained for actin and ZO-2, ZO-3, or occludin. Staining of MDCK monolayers with fluorescein isothiocyanateconjugated phalloidin (Fig. 3A) reveals a continuous apical actin belt in the same focal plane as the TJ. ZO-2, ZO-3, and occludin (Fig. 3, B-D) show continuous staining along cell borders typical of these TJ proteins (3, 5, 13) . When cells are treated with cytochalasin D and costained for actin (Fig. 3, H-J ) and ZO-2 (Fig. 3E ), ZO-3 (Fig. 3F ), or occludin (Fig. 3G) , the continuous junctional staining pattern of TJ proteins seen in control cells was found to be reorganized into aggregates which colocalize with similar aggregates of actin. The in vivo colocalization of ZO-2, ZO-3, and occludin with actin under conditions where TJ integrity is compromised indicates that the in vitro binding interactions identified above also play a role in vivo.
Binding Interactions-As it was shown previously that ZO-1 (22, 27) and ZO-3 (5) bind to the C-terminal, cytoplasmic tail of occludin, we tested whether ZO-2 shares this ability. Itoh et al. (25) provided data which indicated that ZO-2 has occludin binding capability; however, the binding assays were performed with whole cell lysates, so the possibility that this interaction is mediated by a third protein could not be excluded. We tested for direct binding of ZO-2 to occludin by incubating purified recombinant ZO-2 with either resin-immobilized GST-occludin or GST alone. Fig. 4A shows that occludin specifically retains ZO-2, while GST alone does not. As an additional negative control, a 6-histidine tagged Rubella virus capsid protein (a gift from Christian Oker-Blom, VTT Biotechnology and Food Research, Helsinki, Finland) did not bind to occludin under identical conditions (data not shown), showing that the occludin construct does not have nonspecific binding capabilities, and that the interaction with ZO-2 was not due to the 6-histidine tag.
To date, the experimental evidence provided for a binding interaction between ZO-1 and ZO-2 (22, 25) does exclude the possibility that a third unidentified protein is acting as a bridging protein. In the present study, purified recombinant ZO-2 or negative control peptide immobilized on affinity resin was incubated with in vitro translated ZO-1, and bound complexes were resolved by SDS-PAGE and autoradiography to detect 5, and 7) , indicating that these proteins do not bind to actin filament ends. Pellet fractions were immunoblotted with anti-ZO-2 ( lanes 3 and 4) , anti-ZO-3 (lanes 5 and 6), and anti-occludin (lanes 7 and 8) . B, low speed sedimentation assay to test F-actin cross-linking ability of ZO-2, ZO-3, and occludin. F-actin was incubated alone (lanes 1-2, 4 -5, and 7-8) or with ZO-2 (lane 3), ZO-3 (lane 6), or occludin (lane 9), centrifuged at low speed (10,000 ϫ g), and visualized by Coomassie staining of supernatant (S) and/or pellet (P) fractions. The majority of F-actin is found in the supernatant under these conditions (lanes 1, 4, and 7) , compared with the pellet fraction  (lanes 2, 5, and 8) . When ZO-2, ZO-3, or occludin is added, the amount of F-actin in the pellet is unchanged, indicating that neither ZO-2, ZO-3, nor occludin has any detectable F-actin cross-linking activity. 
FIG. 4. ZO-2 directly binds both occludin and ZO-1.
A, purified recombinant ZO-2 (lane 1) was incubated with affinity resin containing the C-terminal, cytoplasmic domain of occludin as a GST fusion protein (lane 2) or GST alone (lane 3). Bound material was eluted, subjected to SDS-PAGE, and immunoblotted with anti-ZO-2. ZO-2 is retained by GST-occludin but not by GST alone. B, 35 S-labeled in vitro translated ZO-1 (lane 1) was incubated with affinity resin containing either ZO-2 (lane 2) or negative control 6-histidine-tagged peptide (lane 3). Bound material was eluted, subjected to SDS-PAGE, and autoradiography. ZO-1 is specifically retained by ZO-2 but not the negative control polypeptide. 35 S-labeled ZO-1. Fig. 4B shows that the ZO-2 affinity column retains ZO-1 while the negative control peptide does not. We previously confirmed the identity of the transcription/translation product shown in lanes 1 and 2 (Fig. 4) as ZO-1 by immunoblot (5). As a negative control, transcription/translation with empty vector (pBluescript SKϩ) results in no visible products (data not shown). The faster-migrating multiple bands visible in this sample likely result from proteolytic degradation or incomplete transcription due to the large size of the ZO-1 transcript (Ͼ5 kilobases). This finding confirms that the ZO-2⅐ZO-1 interaction is direct.
ZO-1, ZO-2, and ZO-3 Complex Formation-The finding that ZO-1 binds directly to both ZO-2 (Fig. 4) and ZO-3 (5), while ZO-2 and ZO-3 do not interact directly (5), makes it possible that ZO-1 may act as a molecular bridge, mediating the interaction of ZO-1, ZO-2, and ZO-3 into a coimmunoprecipitating heterotrimeric complex (3, 5, 26) . Alternatively, available data are also consistent with the presence of distinct ZO-1⅐ZO-2 and ZO-1⅐ZO-3 complexes (Fig. 5A) . In order to discern between these alternatives, we performed a series of low stringency immunoprecipitations using anti-ZO-1, anti-ZO-2, or anti-ZO-3 antibodies to identify coimmunoprecipitating proteins (Fig.  5B) . As shown previously (3, 5, 26, 36) , both ZO-2 and ZO-3 coimmunoprecipitate with anti-ZO-1 (Fig. 5B, lane 1) . This coimmunoprecipitation was the means by which ZO-2 (3, 36) and ZO-3 (5, 26) were identified and characterized. When a low stringency immunoprecipitation is performed using anti-ZO-2 (Fig. 5B, lane 2) , ZO-1 coimmunoprecipitates but ZO-3 does not. The unidentified protein migrating at ϳ180 kDa between ZO-1 and ZO-2 is believed to be a nonspecific band related to the rabbit anti-ZO-2 antibody used (3). When anti-ZO-3 is used as the immunoprecipitation antibody under low stringency conditions, ZO-1 again coimmunoprecipitates but ZO-2 does not (Fig.  5B, lane 3) . To confirm the absence of ZO-3 and ZO-2 from the material shown in lanes 2 and 3 of Fig. 5B , respectively, low stringency immunoprecipitations using anti-ZO-2 and anti-ZO-3 were followed by high stringency immunoprecipitations with anti-ZO-3 and anti-ZO-2 antibodies (Fig. 5C) . No ZO-3 is detected in the anti ZO-2 low stringency immunoprecipitation (Fig.  5C, lane 1) , and no ZO-2 is found in the anti-ZO-3 low stringency immunoprecipitation (Fig. 5C, lane 2) . To demonstrate the efficacy of this sequential immunoprecipitation approach, Fig. 5D shows that ZO-2 can be sequentially immunoprecipitated from the anti-ZO-2 low stringency immunoprecipitation (Fig. 5D, lane 1) . Similarly, ZO-3 can be sequentially immunoprecipitated from a low stringency anti-ZO-1 immunoprecipitation (Fig. 5D, lane 2) . Combined, these data indicate that two distinct complexes exist at the TJ: ZO-1⅐ZO-2 and ZO-1⅐ZO-3.
To further corroborate the existence of two separate complexes involving ZO-1, ZO-2, and ZO-3, MDCK cells overexpressing an exogenous, full-length ZO-3 construct (MDCK/Z3; Ref. 5) were examined. MDCK/Z3 cells express significantly more ZO-3 than parental cells (Fig. 6A) . When ZO-1 is immunoprecipitated from MDCK/Z3 cell extracts under low stringency conditions, less ZO-2 coimmunoprecipitates from MDCK/Z3 cells (Fig. 6B, lane 1) than from parental MDCK cells (Fig. 6B, lane 2) . This indicates that in cells overexpressing ZO-3, less ZO-1 is associating with ZO-2, and ZO-1⅐ZO-3 becomes the predominant complex. Conversely, when low stringency immunoprecipitations with anti-ZO-2 are performed, less ZO-1 coimmunoprecipitates from MDCK/Z3 cells (Fig. 6B,  lane 3) than from parental MDCK cells (Fig. 6B, lane 4) , with no ZO-3 coimmunoprecipitating from either cell type. Finally, as expected, there is more ZO-1 coimmunoprecipitated by anti-ZO-3 in MDCK/Z3 cells (Fig. 6B, lane 5) than in parental MDCK cells (Fig. 6B, lane 6) , and no ZO-2 is coimmunoprecipitated from either cell line. Combined, these results substantiate the existence of distinct ZO-1⅐ZO-2 and ZO-1⅐ZO-3 complexes. They further indicate that the level of ZO-1⅐ZO-3 can be increased at the expense of ZO-1⅐ZO-2 by the overexpression of ZO-3. Finally, we also performed an in vitro binding experiment to determine if a three-member ZO-2⅐ZO-1⅐ZO-3 complex could be reconstituted in vitro. The presence of in vitro translated ZO-1 did not result in ZO-2 retention on a ZO-3 affinity column (data not shown), supporting the evidence that ZO-1 does not act as a bridge between ZO-2 and ZO-3.
DISCUSSION
While considerable progress has been made in the identification of TJ-associated proteins, the next level of understanding in TJ biology will be gained by determining exactly how these proteins interact and how those interactions relate to TJ physiology. In this study, we have explored the interactions of various TJ proteins and the linkage of those proteins with the actin cytoskeleton. We endeavored to provide direct binding evidence, with the belief that such data will permit more accurate testing of the molecular mechanisms underlying function. By performing binding experiments with purified recombinant proteins in vitro we have identified novel binding interactions, and confirmed interactions that were previously suggested by indirect evidence.
ZO-1 has been theorized to link the actin cytoskeleton to the TJ via an actin⅐ZO-1⅐occludin complex (22, 23) , although the existing evidence for this linkage does not rule out the participation of other unidentified proteins. The results of our study indicate that there are other mechanisms for linking actin to the TJ, as ZO-2, ZO-3, and occludin can each directly interact with F-actin in vitro. More detailed characterization of this actin-TJ protein interaction using actin cosedimentation experiments with sheared actin filaments revealed that ZO-2, ZO-3, and occludin do not bind F-actin ends and are likely sidebinding proteins. Furthermore, based on low speed sedimentation assay results, it is unlikely that any of these three proteins have any cross-linking activity. This would indicate that ZO-2, ZO-3, and occludin act to tether actin filaments at the junctional membrane, while different proteins may be involved in forming bundled actin networks. The in vitro actin cosedimentation data is further substantiated by the finding that ZO-2, ZO-3, and occludin colocalize with cytochalasin D-disrupted actin aggregates at cell borders in vivo. Together, these results indicate that actin has multiple potential binding partners at the TJ. Whether all of these interactions occur simultaneously or shift depending on the physiological state of the TJ remains to be determined.
The observed interactions between F-actin and ZO-1, ZO-2, and ZO-3 may be due to the homology and conserved domains present among the three ZO proteins. The data of Fanning et al. (22) indicates the putative actin-binding domain of ZO-1 resides C-terminal to the GUK domain, an area that encompasses the proline-rich region. A particularly novel finding is that the transmembrane protein occludin can interact with F-actin either directly or indirectly via a linkage with ZO-1, ZO-2, or ZO-3. Given that we know occludin plays a role in modulating TJ permeability (30, (43) (44) (45) , multiple linkage mechanisms may provide the versatility required for differential regulation. Recently, Kojima et al. (24) have also addressed the question of TJ-cytoskeleton attachment. In rat hepatocytes, treatment with the actin depolymerizing drug mycalolide B caused disappearance of both the circumferential actin filaments and occludin, while intact tight junction strands remained, leading them to hypothesize that occludin, but not other transmembrane proteins play a role in the linkage between the actin cytoskeleton and TJ.
Our finding that ZO-2 binds to the C-terminal 147 amino acids of occludin confirms and extends the result of Itoh et al. (25) . Based on these results and previous work (5, 22, 27) , we now have evidence that this region of occludin is capable of binding all three ZO proteins. Differential binding of the ZO proteins to occludin may indicate functional redundancy, or may be a means of TJ regulation. It is obviously also important to determine if the ZO proteins bind any of the other transmembrane elements at the TJ.
Based on coimmunoprecipitation experiments (3, 5, 26) and the fact that ZO-2 and ZO-3 do not interact directly (5) while ZO-1 binds to both ZO-3 (5) and ZO-2 (Fig. 4) , we originally hypothesized that ZO-1 may act as a linker mediating the association of ZO-1, ZO-2, and ZO-3 in a three-member complex. However, existing data could also be explained by the presence of two independent complexes of ZO-1⅐ZO-2 and ZO-1⅐ZO-3. We sought to resolve this issue by performing a series of low stringency coimmunoprecipitation experiments using antibodies to all three ZO proteins. These experiments provide evidence that ZO-1⅐ZO-2 and ZO-1⅐ZO-3 exist as independent complexes (Figs. 5 and 6 ). If a trimeric ZO-1⅐ZO-2⅐ZO-3 complex exists, it is either not a predominant species, or it may be an undetectable transient phenomenon. Further confirmation of two distinct complexes is provided by the finding that a shift in the normal balance of these two complexes can be induced in MDCK cells overexpressing ZO-3. One interpretation is that ZO-1 has a higher affinity for and will preferentially bind to ZO-3 rather than ZO-2 if ZO-3 levels are not limiting in the cell. The results described here demonstrate that ZO-2 binds directly to ZO-1 and occludin, and ZO-2, ZO-3, and occludin can directly associate with the sides of actin filaments. Previously published results indicate that ZO-1 binds F-actin, although direct binding has not been demonstrated. Additionally, our evidence supports the existence of two independent complexes comprising of ZO-1⅐ZO-2 and ZO-1⅐ZO-3, rather than a three-member ZO-1⅐ZO-2⅐ZO-3 complex. The binding interactions among other TJ proteins and whether all of these interactions occur simultaneously remains to be determined.
A second interpretation is that in the presence of saturating levels of ZO-3, ZO-3 competes with ZO-2 for binding to ZO-1.
In summary, the experiments outlined here reveal novel binding interactions among TJ-associated proteins. A schematic representation of all known TJ protein interactions is shown in Fig. 7 . While this diagram indicates a high degree of complexity, and provides a conceptual framework for the study of TJ physiology, much information is yet to be attained. For example, it will be of interest to determine if all of these possible linkages exist at the TJ simultaneously, or if there are preferential subgroupings related to the physiological state of the TJ. The role of other transmembrane elements within the TJ complex must also be determined. However, our findings reveal an intricacy that may be indicative of complex regulatory mechanisms, and/or functional redundancy. The information obtained in this study will provide a basis for further investigation of TJ assembly and physiology.
